Возможности реализации репродуктивной функции у больных раком молочной железы

1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024; 74(3):229-63. https://dx.doi.org/10.3322/caac.21834
2. Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Состояние онкологической помощи населению России в 2024 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2025. 275 с. [Kaprin A.D., Starinsky V.V., Shakhzadova A.O., ed. State of oncological care for the population of Russia in 2024. Moscow: P. Hertsen MORI – branch of the NMRC of Radiology of the Ministry of Health of Russia; 2025. 275 p. (in Russian)].
3. Paluch-Shimon S., Cardoso F., Partridge A.H., Abulkhair O., Azim H.A., Bianchi-Micheli G. et al. ESO-ESMO 5th International consensus guidelines for breast cancer in young women (BCY5). Ann. Oncol. 2022; 33(11): 1097-118. https://dx.doi.org/10.1016/j.annonc.2022.07.007
4. Harbeck N., Penault-Llorca F., Cortes J., Gnant M., Houssami N., Poortmans P. et al. Breast cancer. Nat. Rev. Dis. Primers. 2019; 5(1): 66. https://dx.doi.org/10.1038/s41572-019-0111-2
5. Britt K.L., Cuzick J., Phillips K.A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer. 2020; 20(8): 417-36. https://dx.doi.org/10.1038/s41568-020-0266-x
6. Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T. et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019; 30(8): 1194-220. https://dx.doi.org/10.1093/annonc/mdz173
7. Daly M.B., Pal T., Berry M.P., Buys S.S., Dickson P., Domchek S.M. et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021. J. Natl. Compr. Canc. Netw. 2021; 19(1): 77-102. https://dx.doi.org/10.6004/jnccn.2021.0001
8. Tung N., Domchek S.M., Stadler Z., Nathanson K.L., Couch F., Garber J.E. et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat. Rev. Clin. Oncol. 2016; 13(9): 581-8. https://dx.doi.org/10.1038/nrclinonc.2016.90
9. Farhud D.D., Zokaei S., Keykhaei M., Hedayati M., Zarif Yeganeh M. In-vitro fertilization impact on the risk of breast cancer: a review article. Iran J. Public Health. 2021; 50(3): 438-47. https://dx.doi.org/10.18502/ijph.v50i3.5583
10. Winship A.L., Stringer J.M., Liew S.H., Hutt K.J. The importance of DNA repair for maintaining oocyte quality in response to anti-cancer treatments, environmental toxins and maternal ageing. Hum. Reprod. Update. 2018; 24(2): 119-34. https://dx.doi.org/10.1093/humupd/dmy002
11. Lambertini M., Peccatori F.A., Demeestere I., Amant F., Wyns C., Stukenborg J.B. et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2020; 31(12): 1664-78. https://dx.doi.org/10.1016/j.annonc.2020.09.006
12. Cobo A., Garcia-Velasco J.A., Remohí J., Pellicer A. Oocyte vitrification for fertility preservation in women with cancer: a systematic review and meta-analysis. Hum. Reprod. Update. 2021; 27(3): 538-58. https://dx.doi.org/10.1093/humupd/dmaa055
13. Pal M., Das D., Pandey M. Understanding genetic variations associated with familial breast cancer. World J. Surg. Oncol. 2024; 22: 271. https://dx.doi.org/10.1186/s12957-024-03553-9
14. Ntemou E., Vidal P.D., Alexandri C., Van den Steen G., Lambertini M., Demeestere I. Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. Sci. Rep. 2022; 12(1): 1658. https://dx.doi.org/10.1038/s41598-022-05357-x
15. Wu C., Wu T., Chen D., Wei S., Tang W., Xue L. et al. The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: a review of current evidence. Front. Endocrinol. 2022; 13: 1025018. https://dx.doi.org/10.3389/fendo.2022.1025018
16. Wang Y., Li Y., Liang J., Zhang N., Yang Q. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: an updated meta-analysis. Front. Oncol. 2022; 12: 859974. https://dx.doi.org/10.3389/fonc.2022.859974
17. Raveendran C., Meloot S.S., Yadev I.P. Clinical and biochemical amenorrhea in premenopausal patients with breast cancer treated with chemotherapy - a prospective cohort study. BMC Cancer. 2025; 25(1): 753. https://dx.doi.org/10.1186/s12885-025-14159-z
18. Anderson R.A., Amant F., Braat D., D'Angelo A., Chuva de Sousa Lopes S.M., Demeestere I. et al. ESHRE guideline: female fertility preservation. Hum. Reprod. Open. 2020; 2020(4): hoaa052. https://dx.doi.org/10.1093/hropen/hoaa052
19. Turan V., Bedoschi G., Lee D.Y., Barbosa C.P., de Oliveira R., Sacinti K.G. et al. Trends and regional differences for fertility preservation procedures in women with breast cancer. Clin. Breast Cancer. 2025; 25(2): 108-16.e1. https://dx.doi.org/10.1016/j.clbc.2024.11.002
20. Melo P., Eapen A., Chung Y., Jeve Y., Price M.J., Sunkara S.K. et al. Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis. Cochrane Database Syst. Rev. 2025; 7(7): CD012586. https://dx.doi.org/10.1002/14651858.CD012586.pub2
21. Haskoylu S., Sahin S.B., Altıntas A., Yildiz S., Bildik G., Benlioglu C. et al. The impact of conventional chemotherapy regimens and targeted drugs on ovarian function in breast cancer patients. Reprod. Sci. 2026; 33(4): 657-71. https://dx.doi.org/10.1007/s43032-026-02067-x
22. Arecco L., Perachino M., Damassi A., Latocca M.M., Conte B., Tagliamento M. et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum. Reprod. 2022; 37(5): 954-68. https://dx.doi.org/10.1093/humrep/deac035
23. Boutas I., Kontogeorgi A., Koufopoulos N., Dimas D.T., Sitara K., Kalantaridou S.N. et al. Breast cancer and fertility preservation in young female patients: a systematic review of the literature. Clin. Pract. 2023; 13(6): 1413-26. https://dx.doi.org/10.3390/clinpract13060127
24. Raimondo D., Doglioli M., Forastiere C., Vicenti R., Schirripa M., Pazzaglia E. et al. Breast cancer and ovarian tissue cryopreservation: SWOT analysis. J. Clin. Med. 2026; 15(11): 4083. https://dx.doi.org/10.3390/jcm15114083
25. Kumar P., Rao S., Mundkur A., Adiga P., Poojari V.G., Ullagaddi R.K. Random start ovarian stimulation. J. Hum. Reprod. Sci. 2022; 15(2): 200-3. https://dx.doi.org/10.4103/jhrs.jhrs_172_21
26. Бирюкова А.М., Назаренко Т.А., Мартиросян Я.О., Ошкина Е.В. Особенности проведения программ экстракорпорального оплодотворения, направленных на сохранение репродуктивного материала у больных раком молочной железы. Акушерство и гинекология. 2025; 4: 61-70. https://dx.doi.org/10.18565/aig.2025.38 [Biryukova A.M., Nazarenko T.A., Martirosyan Ya.O., Oshkina E.V. Use of in vitro fertilization programs to preserve reproductive material in patients with breast cancer. Obstetrics and Gynecology. 2025; (4): 61-70 (in Russian). https://dx.doi.org/10.18565/aig.2025.38].
27. Bercaire L.M.N., Cavagna M., Donadio N. F., Rocha A. R., Portela R., Alves V. R. et al. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation. JBRA Assist. Reprod. 2020; 24(3): 257-64. https://dx.doi.org/10.5935/1518-0557.20200002
28. Goldrat O., Van Den Steen G., Gonzalez-Merino E., Dechène J., Gervy C., Delbaere A. et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reprod. Biol. Endocrinol. 2019; 17(1): 3. https://dx.doi.org/10.1186/s12958-018-0443-x
29. Oktay K., Turan V., Bedoschi G., Pacheco F.S., Moy F. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 2018; 36(15_suppl): 12120. https://dx.doi.org/10.1200/JCO.2018.36.15_suppl.12120
30. Lifshitz D., Ben-Haroush A., Meirow D., Orvieto R., Vaturi Meirman D., Elbaz L. et al. Letrozole or tamoxifen co-administration during fertility preservation for patients affected by breast cancer. Reprod. Biomed. Online. 2025; 51(5): 104878. https://dx.doi.org/10.1016/j.rbmo.2025.104878
31. Yoshida T., Takahashi O., Suzuki Y., Ota E., Hirata T. The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen-sensitive breast cancer: a systematic review and meta-analysis. Reprod. Med. Biol. 2023; 22(1): e12543. https://dx.doi.org/10.1002/rmb2.12543
32. Meirow D., Raanani H., Maman E., Paluch-Shimon S., Shapira M., Cohen Y. et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil. Steril. 2014; 102(2): 488-95.e3. https://dx.doi.org/10.1016/j.fertnstert.2014.05.017
33. Pereira N., Voskerician G., Rosenwaks Z. Random-start ovarian stimulation for fertility preservation: a systematic review and meta-analysis. J. Gynecol. Obstet. Hum. Reprod 2021; 50(10): 102223. https://dx.doi.org/10.1016/j.rbmo.2017.06.002
34. Oktay K., Harvey B.E., Partridge A.H., Quinn G.P., Reinecke J., Taylor H.S. et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update. J. Clin. Oncol. 2018; 36(19): 1994-2001. https://dx.doi.org/10.1200/JCO.2018.78.1914
35. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil. Steril. 2019; 112(6): 1022-33. https://dx.doi.org/10.1016/j.fertnstert.2019.09.013
36. Zheng F., Zhu B., Feng Q., Wu L., Cui Y., Liu Y. et al. Protective effect of gonadotropin releasing hormone agonist against chemotherapy induced ovarian dysfunction: a meta analysis. Oncol. Lett. 2019; 17(6): 5319-26. https://dx.doi.org/10.3892/ol.2019.10252
37. Rodriguez-Wallberg K.A., Hao X., Marklund A., Johansson A.L.V., Borgström B., Lissmats A. et al. Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths – a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden. EClinicalMedicine. 2023; 67: 102335. https://dx.doi.org/10.1016/j.eclinm.2023.102335
38. Антух И.Е., Шпирко В.О., Назаренко Т.А., Мартиросян Я.О., Бирюкова А.М., Хохлова С.В., Тумян Г.С. Медикаментозная защита яичников в период проведения программной противоопухолевой лекарственной терапии у больных с классической лимфомой Ходжкина и неходжкинскими лимфомами. Клиническая онкогематология. 2024; 17(1): 59-65. https://dx.doi.org/10.21320/2500-2139-2024-17-1-59-65 [Antukh I.E., Shpirko V.O., Nazarenko T.A., Martirosyan Ya.O., Biryukova A.M., Khokhlova S.V., Tumyan G.S. Pharmacological protection of ovaries during program drug chemotherapy in classical Hodgkin lymphoma and non-Hodgkin lymphoma patients. Clinical Oncohematology. 2024; 17(1): 59-65 (in Russian). https://dx.doi.org/10.21320/2500-2139-2024-17-1-59-65].
39. Leonard R.C.F., Adamson D.J.A., Bertelli G., Mansi J., Yellowlees A., Dunlop J. et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017; 28(8): 1811-6. https://dx.doi.org/10.1093/annonc/mdx184
40. Kim S., Lee S., Park H.T., Song J.Y., Kim T. Genomic consideration in chemotherapy-induced ovarian damage and fertility preservation. Genes (Basel). 2021; 12(10): 1525. https://dx.doi.org/10.3390/genes12101525
41. Gellner S.E., Pors S.E., Kristensen S.G., Bay-Bjørn A.M., Ernst E., Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J. Assist. Reprod. Genet. 2018; 35(4): 561-70. https://dx.doi.org/10.1007/s10815-018-1144-2
42. Bittar J., Akouri M., Francis J., Tsiartas P., Akouri R. Three decades of ovarian tissue cryopreservation in western Sweden: indications, techniques, and reproductive outcomes in a regional program. Reprod. Med. 2026; 7(2): 19. https://dx.doi.org/10.3390/reprodmed7020019
43. Lin W., Titus S., Moy F., Ginsburg E.S., Oktay K. Ovarian aging in women with BRCA germline mutations. J. Clin. Endocrinol. Metab. 2017; 102(10): 3839-47. https://dx.doi.org/10.1210/jc.2017-00765
44. Nogueira D., Fajau-Prevot C., Clouet M., Assouline P., Deslandres M., Montagut M. Outcomes of different in vitro maturation procedures for oocyte cryopreservation for fertility preservation and yet another live birth in a cancer patient. Life (Basel). 2023; 13(6): 1355. https://dx.doi.org/10.3390/life13061355
45. van Tilborg T.C., Derks-Smeets I.A., Bos A.M., Oosterwijk J.C., van Golde R.J., de Die-Smulders C.E. et al. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? Hum. Reprod. 2016; 31(11): 2651-9. https://dx.doi.org/10.1093/humrep/dew242
46. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil. Steril. 2020; 113(3): 485-90. https://dx.doi.org/10.1016/j.fertnstert.2019.12.015
47. Oktay K., Bedoschi G., Goldfarb S.B., Taylan E., Titus S., Palomaki G.E. et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil. Steril. 2020; 113(6): 1251-60.e1. https://dx.doi.org/10.1016/j.fertnstert.2020.01.033
48. Pavone M.E., Hirshfeld-Cytron J., Tingen C., Thomas C., Thomas J., Lowe M.P. et al. Human ovarian tissue cortex surrounding benign and malignant lesions. Reprod. Sci. 2014; 21: 582-9. https://dx.doi.org/10.1177/1933719113506498
49. Turan V., Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum. Reprod. Update. 2020; 26(1): 43-57. https://dx.doi.org/10.1093/humupd/dmz043
50. Gasparri M.L., Di Micco R., Zuber V., Taghavi K., Bianchini G., Bellaminutti S. et al. Ovarian reserve of women with and without BRCA pathogenic variants: a systematic review and meta-analysis. Breast. 2021; 60: 155-62. https://dx.doi.org/10.1016/j.breast.2021.09.006
51. Sighinolfi G., Grandi G., Barbieri E., Venturelli M., Piombino C., Melotti C. et al. Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome. Commun. Med. (Lond). 2025; 5(1): 70. https://dx.doi.org/10.1038/s43856-025-00788-9
52. Oktay K.H., Turan V., Titus S., Stobezki R., Liu L. The role of declining ataxia-telangiectasia-mutated (ATM) function in oocyte aging. Cell. Death Discov. 2024; 10: 302. https://dx.doi.org/10.1038/s41420-024-02041-z
53. Emori C., Boucher Z., Bolcun-Filas E. CHEK2 signaling is the key regulator of oocyte survival after chemotherapy. Sci. Adv. 2023; 9(42): eadg0898. https://dx.doi.org/10.1126/sciadv.adg0898
54. Kim S.Y., Seo S.K., Choi Y.M., Jeon G.H., Lee E.J., Lee J.R. et al. Genetic variants associated with premature ovarian failure: a systematic review. Menopause. 2021; 28(11): 1291-301. https://dx.doi.org/10.1097/GME.0000000000001844
55. Partridge A.H., Niman S.M., Ruggeri M., Peccatori F.A., Azim H.A., Colleoni M. et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N. Engl. J. Med. 2023; 388(18): 1645-56. https://dx.doi.org/10.1056/NEJMoa2212856
56. Moravek M.B., Confino R., Lawson A.K., Smith K.N., Kazer R.R., Klock S.C. et al. Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation. Breast. Cancer Res. Treat. 2021; 186(2): 429-37. https://dx.doi.org/10.1007/s10549-020-06031-4
57. Chlebowski R.T., Anderson G.L., Aragaki A.K., Manson J.E., Stefanick M.L., Pan K. et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's health initiative randomized clinical trials. JAMA. 2020; 324(4): 369-80. https://dx.doi.org/10.1001/jama.2020.9482
58. Chlebowski R.T., Aragaki A.K. The Women's health initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Menopause. 2023; 30(4): 454-61. https://dx.doi.org/10.1097/gme.0000000000002154
59. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. 2019; 394(10204): 1159-68. https://dx.doi.org/10.1016/S0140-6736(19)31709-X
60. Ito A., Katagiri Y., Fukuda Y., Morita M. Dynamic changes in serum steroid hormone during the first trimester of pregnancy between infertile women conceiving with and without hormone replacement therapy. Heliyon. 2021; 7(10): e08100. https://dx.doi.org/10.1016/j.heliyon.2021.e08100
61. Blondon M., Timmons A.K., Baraff A.J., Floyd J.S., Harrington L.B., Korpak A.M. et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women veterans. Menopause. 2021; 28(10): 1125-9. https://dx.doi.org/10.1097/GME.0000000000001823

Поступила 08.06.2026

Принята в печать 15.09.2026